This pathway has been noted in 70% of the inflammation subclass in ICC, characterized by activation of the STAT3 and cytokine pathways and improved prognosis.[87] Furthermore, the JAK2 inhibitor AZD1480 has been demonstrated to inhibit Stat3 signaling and exhibit anti-tumor efficacy in solid tumor cell lines [88]. This evidence concerns the gene STAT3 and intrahepatic cholangiocarcinoma.